Deciphering breast cancer: from biology to the clinic
E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
[HTML][HTML] The genomic landscape of endocrine-resistant advanced breast cancers
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
[HTML][HTML] Tumor heterogeneity in breast cancer
G Turashvili, E Brogi - Frontiers in medicine, 2017 - frontiersin.org
Breast cancer is a heterogeneous disease and differs greatly among different patients
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …
Coming of age: ten years of next-generation sequencing technologies
Since the completion of the human genome project in 2003, extraordinary progress has
been made in genome sequencing technologies, which has led to a decreased cost per …
been made in genome sequencing technologies, which has led to a decreased cost per …
Therapeutic targeting of long non-coding RNAs in cancer
Long non-coding RNAs (lncRNAs) represent a significant population of the human
transcriptome. Many lncRNAs exhibit cell-and/or tissue/tumor-specific expression, making …
transcriptome. Many lncRNAs exhibit cell-and/or tissue/tumor-specific expression, making …
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …
the driver mutations conferring clonal advantage and the mutational processes generating …
[HTML][HTML] The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …
heterogeneity are important challenges in treating the disease. In this study, we sequence …
[HTML][HTML] Genomic evolution of breast cancer metastasis and relapse
Patterns of genomic evolution between primary and metastatic breast cancer have not been
studied in large numbers, despite patients with metastatic breast cancer having dismal …
studied in large numbers, despite patients with metastatic breast cancer having dismal …